Ocugen, Inc.
Ocugen, Inc. (OCGN): 11 pipeline candidates · 2 upcoming catalysts · ~5 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.7 months
D/E 8.80 · 0% dilution
Lead: Phase 3
11 candidates
2 upcoming, next in ~102d
N/A
A transparent, data-derived signal for Ocugen, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$416.4M
Cash
$32.2M
Quarterly Burn
$21.8M
Runway
4.7 mo
Revenue
$1.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| neocart | Phase 3 |
| ocu200 | Phase 1 |
| ocu400 | Phase 3 |
| ocu400 med dose | Phase 1/Phase 2 |
| ocu400 second eye dosing | Phase 1/Phase 2 |
| ocu410 | Phase 2/Phase 3 |
| ocu410st | Phase 2/Phase 3 |
| ocu500 | Phase 1 |
| ocu510 | Phase 2/Phase 3 |
| ocu520 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
134
Total value held
$201.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 27,608,222 | $50.0M |
| millennium management llc | 13,932,192 | $25.2M |
| state street corp | 9,670,191 | $17.5M |
| marshall wace, llp | 8,052,350 | $14.6M |
| blackrock, inc. | 7,304,979 | $13.2M |
| rtw investments, lp | 6,666,666 | $12.1M |
| geode capital management, llc | 4,227,104 | $7.7M |
| jane street group, llc | 3,767,655 | $6.8M |
| gmt capital corp | 3,505,398 | $6.3M |
| citadel advisors llc | 3,179,957 | $5.8M |
Showing top 10 of 134 institutional holders of Ocugen, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Ocugen, Inc.'s pipeline?
Ocugen, Inc. (OCGN) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ocugen, Inc.'s lead drug candidate?
Ocugen, Inc.'s most advanced tracked candidate is neocart (Phase 3) for Repair of knee cartilage injuries in adults.
What is Ocugen, Inc.'s next catalyst?
Ocugen, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI" — expected September 28, 2026.
What is Ocugen, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ocugen, Inc. has approximately 4.7 months of cash runway.
What is Ocugen, Inc.'s market capitalization?
Ocugen, Inc.'s market capitalization is approximately $416.4M.
Get the full picture on Ocugen, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.